Suppr超能文献

了解重症肌无力结局中的种族和民族差异:EXPLORE-MG注册研究经验。

Understanding Racial and Ethnic Disparities in Myasthenia Gravis Outcomes: EXPLORE-MG Registry Experience.

作者信息

McLaren Nilay P, Roy Bhaskar, Nowak Richard J

机构信息

Department of Neurology, Yale School of Medicine, New Haven, CT.

出版信息

Neurol Clin Pract. 2025 Aug;15(4):e200503. doi: 10.1212/CPJ.0000000000200503. Epub 2025 Jun 18.

Abstract

BACKGROUND AND OBJECTIVES

Past studies have reported racial and ethnic differences in patients with myasthenia gravis (MG) but either are over a decade old or only examine small samples. To better understand these differences, using the EXPLORE-MG registry, we conducted a retrospective cohort study of racial and ethnic differences in the characteristics and long-term outcomes of patients with MG.

METHODS

Patients with a diagnosis of MG confirmed by one or more of the assessments such as antibody seropositivity, positive single-fiber electromyography, or decremental repetitive nerve stimulation between January 2001 and October 2023 were included in the analysis. For logistic regression models, we performed a complete case analysis, therefore excluding patients with unknown age at onset or history of thymoma. Only patients with 2 years of follow-up data were included in the long-term outcome analysis.

RESULTS

Of 594 study participants, the clinical features of 473 White, 48 African American (AA), 42 Hispanic, and 523 non-Hispanic patients were compared. Hispanic patients (mean age 41.5 ± 20.3 years vs 58.9 ± 19.9 years; < 0.001) were significantly younger at onset compared with non-Hispanic patients, and AA patients were significantly younger at onset compared with White patients (mean age 38.6 ± 17.1 years vs 60.7 ± 19.4 years; < 0.001). AA patients underwent thymectomy more frequently (63.6% vs 29.5%; < 0.001) compared with White patients. After adjusting for covariates, AA patients were approximately 3 times more likely to experience hospitalization for MG crisis or exacerbation compared with White patients (odds ratio 2.77; 95% CI 1.19-6.50; = 0.018).

DISCUSSION

Despite variations in disease severity and clinical profiles, long-term outcomes of patients did not differ. Our findings identify the areas of MG care that vary across racial and ethnic groups, which should be further addressed by clinicians.

摘要

背景与目的

过去的研究报告了重症肌无力(MG)患者存在种族和民族差异,但这些研究要么距今已有十多年,要么仅考察了小样本。为了更好地理解这些差异,我们利用EXPLORE - MG注册研究,对MG患者的特征和长期结局的种族和民族差异进行了一项回顾性队列研究。

方法

纳入2001年1月至2023年10月期间经一项或多项评估(如抗体血清学阳性、单纤维肌电图阳性或递减式重复神经电刺激)确诊为MG的患者进行分析。对于逻辑回归模型,我们进行了完整病例分析,因此排除了发病年龄未知或有胸腺瘤病史的患者。长期结局分析仅纳入有2年随访数据的患者。

结果

在594名研究参与者中,比较了473名白人、48名非裔美国人(AA)、42名西班牙裔和523名非西班牙裔患者的临床特征。与非西班牙裔患者相比,西班牙裔患者发病时明显更年轻(平均年龄41.5±20.3岁对58.9±19.9岁;<0.001),与白人患者相比,AA患者发病时明显更年轻(平均年龄38.6±17.1岁对60.7±19.4岁;<0.001)。与白人患者相比,AA患者胸腺切除术的频率更高(63.6%对29.5%;<0.001)。在调整协变量后,与白人患者相比,AA患者因MG危象或病情加重而住院的可能性大约高出3倍(比值比2.77;95%可信区间1.19 - 6.50;=0.018)。

讨论

尽管疾病严重程度和临床特征存在差异,但患者的长期结局并无不同。我们的研究结果确定了MG护理中不同种族和民族群体之间存在差异的领域,临床医生应进一步关注这些领域。

相似文献

4
Rituximab for myasthenia gravis.利妥昔单抗治疗重症肌无力
Cochrane Database Syst Rev. 2025 Jul 3;7(7):CD014574. doi: 10.1002/14651858.CD014574.pub2.
6
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
9
Corticosteroids for the treatment of Duchenne muscular dystrophy.用于治疗杜氏肌营养不良症的皮质类固醇
Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4.

本文引用的文献

5
Current Treatment of Myasthenia Gravis.重症肌无力的当前治疗方法
J Clin Med. 2022 Mar 14;11(6):1597. doi: 10.3390/jcm11061597.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验